Elisabeth Paietta

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia

Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910

Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Acute lymphoblastic leukemia displays a distinct highly methylated genome

Variational autoencoders learn transferrable representations of metabolomics data

Enhancer retargeting of <i>CDX2</i> and <i>UBTF::ATXN7L3</i> define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

Enhancer Hijacking Drives Oncogenic <i>BCL11B</i> Expression in Lineage-Ambiguous Stem Cell Leukemia

Molecular classification improves risk assessment in adult <i>BCR-ABL1–</i>negative B-ALL

CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials

Three-dimensional chromatin landscapes in T cell acute lymphoblastic leukemia

Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia

Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia

<i>Phf6</i> Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells

Synergistic antileukemic therapies in <i>NOTCH1</i> -induced T-ALL

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia